Retatrutide 10mg

Retatrutide is an investigational synthetic peptide studied as a triple hormone receptor agonist targeting the GIP, GLP-1, and glucagon receptors. In published clinical research, it has been investigated most directly in obesity and type 2 diabetes, where phase 2 studies reported substantial reductions in body weight along with improvements in glycaemic and metabolic markers in selected populations. Research has also examined its effects on endogenous hormone signalling, gastric emptying, and cardiometabolic parameters. Supplied as a lyophilised peptide, this product is intended strictly for laboratory research use only. Retatrutide is not approved by the FDA and remains an investigational molecule under clinical development; reported adverse effects in trials have included mainly gastrointestinal events, with some studies also noting increases in heart rate and other dose-related tolerability findings (Jastreboff et al., 2023; Rosenstock et al., 2023; Urva et al., 2022; Lilly, 2026).